Journal of Health Science and Medical Therapy
E-ISSN 3024-8132 P-ISSN 3024-8116
Volume 3 Issue 02, May 2025, Pp. 165-173
DOI: https://doi.org/10.59653/jhsmt.v3i02.1607

Community-Acquired Pneumonia in Elderly Patients

Mariesela Artanti[1*], Tri Umiana Soleha[2], Shinta Nareswari[3]
Lampung University, Indonesia[1]
Lampung University, Indonesia[2]
Lampung University, Indonesia[3]
Corresponding Email: mariesela00@gmail.com*

Received: 03-03-2025 *Reviewed: 07-04-2025* *Accepted: 10-05-2025*

Abstract

Community-acquired pneumonia (CAP) is a lung infection acquired outside of healthcare facilities and is a leading cause of morbidity and mortality in the elderly. Older adults have a higher risk of CAP due to immune system decline, comorbidities, and impaired respiratory defence mechanisms. Streptococcus pneumoniae is the primary pathogen responsible for CAP in the elderly, followed by Haemophilus influenzae and other atypical bacteria. The diagnosis of CAP in older adults is often challenging due to atypical symptoms such as general weakness and confusion, necessitating chest radiography for confirmation. Treatment depends on disease severity and may involve oral or intravenous antibiotics, oxygen therapy, and close monitoring for complications such as respiratory failure and sepsis. Prevention through pneumococcal and influenza vaccination, personal hygiene maintenance, and management of comorbidities is crucial in reducing CAP incidence and mortality in the elderly.

Keywords: Community-Acquired Pneumonia, Elderly, Lung Infection, Vaccination, Streptococcus Pneumoniae

Introduction

Pneumonia is an acute infection that affects the lung parenchyma, particularly the alveoli, leading to inflammation and accumulation of fluid or pus within the alveolar spaces, thereby impairing oxygen exchange. This condition may be caused by a variety of infectious agents, including bacteria, viruses, and fungi (Inklebarger, 2020). Community-acquired pneumonia (CAP) refers to pneumonia that develops outside healthcare settings, typically resulting from exposure to pathogens present in the everyday environment. The elderly population is particularly susceptible to CAP due to age-related decline in immune function and the presence of comorbidities commonly associated with aging.

The most frequently identified bacterial cause of CAP in elderly individuals is *Streptococcus pneumoniae*, which accounts for the majority of cases (Munarsih, 2018). Other bacterial pathogens such as *Haemophilus influenzae*, *Moraxella catarrhalis*, and atypical

organisms like *Mycoplasma pneumoniae* may also contribute to the disease. In certain cases, gram-negative bacteria such as *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* are implicated, particularly in elderly patients with specific risk factors, such as chronic pulmonary disease or a history of recent hospitalization. Viral infections, including influenza and SARS-CoV-2, may either independently cause pneumonia or exacerbate secondary bacterial pneumonia in this population (Deka, 2022).

Community-acquired pneumonia remains a leading cause of morbidity and mortality worldwide, particularly among vulnerable groups such as infants, children, and older adults. In Indonesia, pneumonia represents one of the primary causes of death due to infectious diseases, with the elderly considered a high-risk group owing to physiological changes associated with aging. Factors such as diminished cough reflex, weakened respiratory muscles, and the presence of comorbidities like diabetes, cardiovascular disease, or chronic obstructive pulmonary disease (COPD) significantly increase the risk of infection and its complications. Hospitalization and mortality rates for CAP are markedly higher among older adults compared to other age groups, especially among those with poor baseline health status.

Management of CAP in elderly patients is determined by disease severity and the presence of underlying comorbidities. Mild cases can often be treated with oral antibiotics, such as amoxicillin or macrolides, while more severe cases may require hospitalization with intravenous antibiotics, oxygen therapy, and close monitoring for complications such as respiratory failure or sepsis (Wijaya, 2021). Preventive strategies are essential; pneumococcal and influenza vaccinations are primary protective measures. Maintaining proper hand hygiene, adopting a healthy lifestyle, and effectively managing existing comorbid conditions are critical in enhancing immune resilience. Elderly individuals who smoke are strongly advised to cease smoking, as it compromises pulmonary defense mechanisms and increases the risk of respiratory tract infections.

Literature Review

The literature defines community-acquired pneumonia (CAP) as an acute infection affecting the lung parenchyma that develops outside healthcare settings (Inklebarger, 2020). In elderly patients, CAP is characterised by unique pathophysiological processes due to age-related immune decline and comorbidities. According to Munarsih (2018), Streptococcus pneumoniae represents the primary causative pathogen, followed by Haemophilus influenzae and atypical bacteria. Jang et al. (2021) describe the pathophysiology as involving pro-inflammatory cytokines that increase alveolar capillary permeability, while Sukmana (2020) notes that this leads to impaired gas exchange and lung consolidation. Safitri (2021) defines the clinical presentation in elderly patients as often atypical, with symptoms like confusion and general weakness rather than the classic triad of fever, cough, and dyspnea. Metlay et al. (2019) establish diagnostic criteria requiring clinical assessment and radiographic confirmation, with severity assessment tools guiding treatment decisions. Wijaya et al. (2021) define appropriate management as including targeted antibiotic therapy based on likely pathogens, with beta-lactams showing efficacy in elderly populations. Preventive measures are defined by Sidiq

(2018) as primarily vaccination against pneumococcal disease and influenza, alongside hygiene practices and lifestyle modifications to reduce risk factors associated with respiratory infections in older adults.

Research Method

The research method employed in this article is a literature review, which refers to a research methodology aimed at synthesizing insights from previous studies, documented experiences, and valuable information found within academic sources. This method involves a critical analysis and comparison of findings from earlier research, offering a comprehensive overview that supports the development of current scientific perspectives (Yam, 2024).

The literature search focused on identifying and analyzing scholarly works relevant to the significance of Community-Acquired Pneumonia (CAP) in elderly patients. The process was conducted by collecting scientific articles and journals published through recognized academic databases such as Google Scholar, PubMed, and other official platforms. Specific inclusion criteria guided the literature selection to ensure the sources' relevance and quality. These criteria included: (1) the articles must be open access, (2) the content must be directly related to the topic of Community-Acquired Pneumonia in elderly patients, and (3) the journals must be available in full-text format to allow for thorough analysis and interpretation. This structured approach enables a comprehensive understanding of the clinical importance, epidemiology, risk factors, pathogens, and management strategies associated with CAP in older adults while highlighting gaps and opportunities for further research.

Result

Definition of Pneumonia

Pneumonia is an acute infection that affects the lungs, particularly the alveoli, resulting in inflammation and the accumulation of fluid or pus. This condition may be triggered by various pathogens—including bacteria, viruses, and fungi—that invade the respiratory tract and proliferate within the pulmonary tissue. Common symptoms of pneumonia include productive cough, fever, shortness of breath, and pleuritic chest pain exacerbated by deep breathing. Risk factors associated with pneumonia comprise extremes of age, weakened immune systems, smoking habits, and comorbid conditions such as diabetes mellitus and chronic lung diseases (Indrawangsa, 2024).

Pneumonia is typically classified based on the setting of acquisition: community-acquired pneumonia (CAP), which occurs outside healthcare facilities, and hospital-acquired pneumonia (HAP), which develops during hospitalization. Diagnosis is established through a combination of medical history, physical examination, chest radiography, and microbiological testing such as sputum culture or antigen detection. Treatment strategies are contingent upon the causative agent—bacterial pneumonia is usually managed with antibiotics, whereas viral pneumonia may require antiviral therapy.

If not appropriately addressed, pneumonia may lead to complications such as respiratory failure, sepsis, and pleural effusion. Preventive measures include pneumococcal and influenza vaccinations, proper hand hygiene, and the avoidance of risk factors such as tobacco smoke and environmental pollutants. Early recognition of symptoms and timely access to medical care are crucial in reducing morbidity and mortality associated with pneumonia.

Community-Acquired Pneumonia in Adults

Community-acquired pneumonia in adults is a lung infection contracted outside of healthcare settings, commonly caused by pathogens such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Mycoplasma pneumoniae*. It is more prevalent in individuals with predisposing factors, including smoking, alcoholism, diabetes mellitus, and chronic obstructive pulmonary disease (COPD) (Muhlis, 2022). Clinical manifestations include productive cough, high fever, chills, dyspnea, and pleuritic chest pain. Diagnosis is based on clinical history, physical examination, chest X-ray, and laboratory testing.

The severity of the illness guides treatment—mild cases can be managed with oral antibiotics, while more severe cases may necessitate hospitalization and intravenous therapy. Preventive strategies encompass vaccination, a healthy lifestyle, and avoidance of risk-enhancing behaviors. If inadequately treated, CAP can lead to severe complications such as lung abscesses, acute respiratory distress syndrome (ARDS), or systemic infections.

Community-Acquired Pneumonia in the Elderly

Community-acquired pneumonia in elderly patients tends to present with greater clinical severity due to age-related immune decline, multiple comorbidities, and diminished cough reflexes, which increase the risk of aspiration. Symptoms in older adults are often atypical and may include general weakness or confusion, rather than the classic signs of fever and cough, thereby necessitating imaging studies such as chest radiography for accurate diagnosis. Treatment involves broad-spectrum antibiotics, oxygen therapy, adequate hydration, and pulmonary rehabilitation to prevent complications like respiratory failure or sepsis (Wantonoro, 2023).

Preventive measures such as pneumococcal and influenza vaccinations, hygiene maintenance, and optimal management of underlying diseases are essential in reducing the incidence of severe infections in this demographic. Prompt detection and comprehensive care can significantly decrease the mortality rate and enhance quality of life among elderly pneumonia patients.

Etiology

Pneumonia can be attributed to a range of infectious agents, including bacteria, viruses, fungi, and parasites that invade pulmonary tissue. The predominant etiological agent of community-acquired pneumonia is *Streptococcus pneumoniae*, a Gram-positive bacterium frequently isolated in clinical cases. Other common pathogens include *Haemophilus influenzae* and *Moraxella catarrhalis*, particularly among individuals with chronic pulmonary disorders such as COPD (Congestrì et al., 2019).

Atypical bacterial pathogens—such as *Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, and *Legionella pneumophila*—are often found in otherwise healthy individuals who have been exposed to specific environmental conditions, such as contaminated water sources. Respiratory viruses, including influenza, SARS-CoV-2, and respiratory syncytial virus (RSV), are especially significant in vulnerable populations such as infants and the elderly. Fungal pathogens like *Pneumocystis jirovecii* typically cause pneumonia in immunocompromised individuals, including those with HIV/AIDS or those undergoing immunosuppressive therapy (Sari, 2021).

Pathogens may reach the lungs via inhalation of respiratory droplets, aspiration from the gastrointestinal tract, or hematogenous spread from distant infection sites. Environmental exposures, such as air pollution and tobacco smoke, further elevate the risk. Accurate identification of the causative pathogen is crucial for selecting appropriate therapeutic interventions (Alfarizi, 2017).

Pathophysiology

The pathophysiological process of pneumonia begins when pathogens evade the host's respiratory defence mechanisms. These defences include the mucociliary apparatus, cough reflex, and innate and adaptive immune responses. Once pathogens reach the alveoli, they trigger an inflammatory response marked by the release of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha (TNF-α) (Jang et al., 2021).

These mediators increase alveolar capillary permeability, leading to fluid exudation into the alveolar spaces and impairing gas exchange. The accumulation of fluid and inflammatory cells in the alveoli results in lung consolidation, which is typically visible on radiographic imaging. Excessive immune response can damage pulmonary tissue and elevate the risk of complications like ARDS or sepsis.

Infections may disseminate more extensively in immunocompromised patients, leading to more severe clinical outcomes. Certain bacteria, such as *Streptococcus pneumoniae*, possess polysaccharide capsules that inhibit phagocytosis, exacerbating the disease course. Consequently, treatment strategies aim to eradicate the causative agents while modulating the inflammatory response to prevent extensive lung damage (Sukmana, 2020).

Clinical Manifestations

The clinical presentation of pneumonia varies depending on the underlying pathogen, disease severity, and the patient's overall health status. Typical symptoms of bacterial pneumonia include high fever, chills, productive cough with purulent sputum, pleuritic chest pain that worsens with deep inspiration, and progressive dyspnea. In viral cases, initial symptoms often resemble influenza, such as fever, myalgia, headache, and dry cough, which may later evolve into productive cough and breathing difficulty (Safitri, 2021).

In elderly patients, symptoms are frequently nonspecific and may manifest as general debility, confusion, or altered mental status without the hallmark features of fever or cough. Individuals with preexisting pulmonary conditions like COPD may experience exacerbations, marked by increased sputum production, worsened dyspnea, and significant hypoxemia.

Severe cases may present with systemic signs such as tachycardia, hypotension, or altered consciousness, indicating the onset of sepsis (Rullian, 2024).

Physical examination findings may include inspiratory crackles, increased tactile fremitus, and signs of lung consolidation such as bronchophony and egophony. If left untreated, pneumonia can progress to serious complications, underscoring the importance of early symptom recognition and prompt intervention.

Risk Factors

Risk factors for pneumonia encompass extremes of age, chronic comorbid conditions such as diabetes and COPD, smoking, and excessive alcohol consumption—all of which compromise pulmonary defense mechanisms. Viral infections like influenza and COVID-19 can predispose individuals to secondary bacterial pneumonia. Immunodeficiency states, including HIV/AIDS and immunosuppressive therapy, further exacerbate susceptibility.

Environmental determinants such as air pollution, poor sanitation, and chemical exposures also contribute to pneumonia risk. Preventive efforts should focus on modifiable risk factors, including smoking cessation and responsible alcohol use, as well as vaccinations and proper hygiene practices.

Diagnosis and Management

The diagnosis of pneumonia is established through patient history, physical examination, and diagnostic imaging—most notably chest X-rays to detect lung infiltrates. Laboratory tests, including complete blood count, C-reactive protein (CRP), and procalcitonin levels, assist in evaluating the inflammatory response. Pathogen identification may be achieved via sputum culture or urinary antigen testing, while arterial blood gas analysis is essential in cases with hypoxemia.

Severity scoring systems such as CURB-65 and the Pneumonia Severity Index (PSI) are used to guide hospitalization decisions. Management is tailored to the etiology and clinical severity; mild cases may be treated with oral antibiotics such as amoxicillin or azithromycin, whereas severe cases require intravenous antibiotics like ceftriaxone or levofloxacin (Metlay et al., 2019).

Patients at high risk for antibiotic resistance may receive broad-spectrum agents such as piperacillin-tazobactam or vancomycin. Supportive care—oxygen therapy, intravenous fluids, and antipyretics—facilitates recovery. Antiviral treatments like oseltamivir or remdesivir are indicated for viral pneumonia. Elderly patients or those with chronic illnesses may benefit from pulmonary rehabilitation. Effective diagnosis and timely management are critical in minimizing complications and improving recovery rates.

Prevention

Preventing pneumonia is imperative for reducing both incidence and mortality, especially among vulnerable groups such as the elderly, children, and individuals with chronic diseases. Pneumococcal and influenza vaccinations are primary preventive measures, particularly for high-risk populations. Additional strategies include frequent handwashing,

mask usage in public areas, and avoiding close contact with infected individuals to limit pathogen transmission (Sidiq, 2018).

Maintaining clean environments with adequate ventilation also mitigates infection risks. Strengthening host immunity through a healthy lifestyle—nutritious diet, regular exercise, and abstaining from smoking and excessive alcohol use—is equally important in reducing susceptibility. For individuals with underlying health conditions, effective disease management is essential in preventing pneumonia complications (Yuliza, 2022).

In healthcare settings, stringent infection control protocols—including hand hygiene, use of personal protective equipment (PPE), and careful care of at-risk patients—are vital for lowering hospital-acquired pneumonia rates. A comprehensive preventive approach can significantly reduce pneumonia incidence and associated mortality (Salukanan, 2018).

Conclusion

Pneumonia is a pulmonary infection caused by various microorganisms, with *Streptococcus pneumoniae* recognized as the primary etiological agent of community-acquired pneumonia. This infection elicits an inflammatory response within the alveoli, disrupting gas exchange and resulting in pulmonary consolidation. Clinical manifestations typically include productive cough, fever, and dyspnea; however, in older adults, the presentation is often atypical, characterized by confusion and generalized weakness. Risk factors associated with the development and progression of pneumonia include advanced age, underlying chronic conditions, tobacco use, and immunosuppressive states—all of which compromise host defense mechanisms and exacerbate disease severity.

Diagnosis involves a comprehensive clinical assessment, including medical history, physical examination, and supporting investigations such as chest radiography and sputum culture. Treatment is determined by the causative pathogen and the severity of the disease, with antibiotic therapy constituting the mainstay of management in bacterial cases. Preventive strategies encompass vaccination—particularly against pneumococcal and influenza infections, maintenance of personal hygiene and adopting a healthy lifestyle. Additionally, the role of healthcare professionals in facilitating early diagnosis, delivering effective treatment, and promoting public health education is critical in reducing the incidence and burden of this condition. Through a multifaceted approach that integrates prevention, early detection, and appropriate therapeutic interventions, the impact of community-acquired pneumonia can be significantly mitigated, thereby enhancing the health outcomes and quality of life among at-risk populations.

Declaration of conflicting interest

The authors declare that there is no conflict of interest in this work.

References

Alfarizi, M. (2017). Pola mikroorganisme penyebab pneumonia dan sensitivitasnya terhadap antibiotik di masyarakat Bandar Lampung [Doctoral dissertation]. Universitas Lampung.

Congestrì, F., Morotti, M., Vicari, R., Pedna, M. F., Sparacino, M., Torri, A., Sambri, V., & Samuelli, M. (2019). Comparison of the novel Immunocatch Legionella test with Sofia Legionella FIA assay and with BinaxNOW Legionella card assay for detection of Legionella pneumophila (Serogroup 1) antigen in urine samples. European Journal of Clinical Microbiology & Infectious Diseases, 57(8), 1-4. https://doi.org/10.1128/JCM.00561-19

Deka, M., Monica, A., & Rachmawaty, D. (2022). Aktivitas antibakteri ekstrak etanol daun wortel (Daucus Carota L.) terhadap Klebsiella pneumoniae dan Pseudomonas aeruginosa. Jurnal Farmasi Tinctura, 4(1), 7-17.

Indrawangsa, N., & Mustika, N. (2024). Defek septum ventrikel dengan komplikasi pneumonia dan gagal tumbuh pada bayi usia 4 bulan di RSUD Wangaya: Sebuah laporan kasus. Intisari Sains Medis, 15(2), 561-567.

Inklebarger, J., Gyer, G., Galanis, N., Michael, J., & Adel, G. (2020). Cinchona bark for the treatment of COVID-19 pneumonia: A modern review of the potential anti-viral therapeutic applications of an old treatment. International Journal of Medical Science and Clinical Invention, 7(05), 4795-4801.

Jang, D., Lee, A.-H., Shin, H. Y., Song, H. R., Park, J. H., Kang, T. B., Lee, S. R., & Yang, S. H. (2021). The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. International Journal of Molecular Sciences, 22(5), 1-16. https://doi.org/10.3390/ijms22052719

Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), 45-67. https://doi.org/10.1164/rccm.201908-1581ST

Muhlis, M., & Novalinda, R. (2022). Hubungan ketepatan peresepan antibiotika berdasarkan metode Gyssens terhadap perbaikan klinis pada pneumonia komunitas di RS swasta kota Yogyakarta. Jurnal Farmasi Dan Sains, 6(1), 1-19.

Munarsih, F., Natadidjaja, I., & Syamsudin. (2018). Pengaruh pemberian antibiotik berdasar panduan terhadap lama tinggal pada pasien pneumonia komunitas di rumah sakit. Jurnal Penyakit Dalam Indonesia, 5(3), 141-141.

Rullian, H. P., Medison, I., Mizarti, D., & Wahyu, D. (2024). Community acquired pneumonia pada lansia. Jurnal Syntax Admiration, 5(5), 1427-1437.

Safitri, A., Nurmadilla, N., & Gayatri, S. (2021). Peranan multivitamin pada pasien geriatri dengan pneumonia. Wal'afiat Hospital Journal, 2(1), 63-74.

Salukanan, R. T., Zulfariansyah, A., & Sitanggang, R. H. (2018). Pola pneumonia nosokomial di unit perawatan intensif Rumah Sakit Umum Pusat Dr. Hasan Sadikin Bandung periode Januari-Desember 2017. Jurnal Anestesi Perioperatif, 6(2), 126-136.

Sari, D. G., Asdie, R. H., & Retnowulan, H. (2021). Perbandingan nilai red cell distribution width terhadap mortalitas pada pasien hospital-acquired pneumonia lansia dan dewasa. Jurnal Penyakit Dalam Indonesia, 8(2), 56-64.

Sidiq, R. (2018). Efektivitas penyuluhan kesehatan dalam meningkatkan pengetahuan kader posyandu tentang pencegahan pneumonia pada balita. AcTion: Aceh Nutrition Journal, 3(1), 22-30.

Sukmana, M., & Yuniarti, F. A. (2020). The pathogenesis characteristics and symptom of Covid-19 in the context of establishing a nursing diagnosis. Jurnal Kesehatan Pasak Bumi Kalimantan, 3(1), 21-28.

Wantonoro, Salmiyati, S., & Faidati, N. (2023). Implementasi program long interdisciplinary community care (POLICE) dimasa pandemik Covid-19 di kota Yogyakarta. Jurnal Abdi Insani, 10(2), 661-670.

Wijaya, A. M., Herawati, F., & Yulia, R. (2021). Kajian literatur: Efektivitas antibiotik golongan beta-laktam pada pasien lansia dengan pneumonia komunitas. Jurnal Sains Farmasi & Klinis, 8(2), 80-87.

Yam, J. (2024). Kajian penelitian: Tinjauan literatur sebagai metode penelitian. Jurnal Empire, 4(1), 41-61.

Yuliza, E., Shifa, A., & Safitri, A. (2022). Asuhan keperawatan pada lansia dengan pneumonia. Jakarta Journal of Health Sciences, 1(4), 125-128.